Poulami Roy

Dr. Poulami Roy

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2022 in Journal of Family Medicine and Primary Care
Verified
Journal Article
Open access
NDNovonil Deb
Novonil Deb
PRPoulami Roy
Poulami Roy
A BSTRACT: Objectives: 1. To assess the impact of COVID-19 lockdown on Internet addiction on first year medical students. 2. To evaluate the associations, if any, between internet addiction, anxiety, depression and stress. Methods: Internet addiction, depression, anxiety and stress among medical students across West Bengal have been studied using Young’s Internet Addiction Test (IAT) scale and the Depression, Anxiety and Stress Scale (DASS-21). A web-based questionnaire was made and circulated via different social media platforms. All interested candidates who gave consent were included in the study. All statistical analyses were done using SPSS version 25.0. Results: The study population consisted of 37.2% of males and 63.8% of females. 80.23% of the participants showed moderate levels of internet addiction. Strong positive correlation was found between anxiety and stress ( r = 0.83, P < 0.05), depression and anxiety ( r = 0.92, P < 0.05) and between depression and stress ( r = 0.86, P < 0.05). Conclusion: The unprecedented ramifications of lockdown are incessant, with internet addiction, magnification in depression, anxiety and stress to name a few. Internet addiction coupled with psychological disorders still remains a matter of concern for medical students.

7 January 2025 in Health Science Reports
Verified
Journal Article
Open access
AGAditya Amit Godbole
Aditya Amit Godbole
PAParas
Paras
MMMaanya Mehra
Maanya Mehra
SBSumitaksha Banerjee
Sumitaksha Banerjee
PRPoulami Roy
Poulami Roy
SJSarang Jagtap
Sarang Jagtap
Introduction: Infection control in intensive care units (ICUs) is crucial due to the high risk of healthcare‐associated infections (HAIs), which can increase patient morbidity, mortality, and costs. Effective measures such as hand hygiene, use of personal protective equipment (PPE), patient isolation, and environmental cleaning are vital to minimize these risks. The integration of artificial intelligence (AI) offers new opportunities to enhance infection control, from predicting outbreaks to optimizing antimicrobial use, ultimately improving patient safety and care in ICUs. Objectives: The primary objectives are to explore AI's impact on predicting HAIs, real‐time monitoring, automated sterilization, resource optimization, and personalized infection control plans. Methodology: A comprehensive search of PubMed and Scopus was conducted for relevant articles up to January 2024, including case series, reports, and cohort studies. Animal studies and irrelevant articles were excluded, with a focus on those considered to have significant clinical relevance. Discussion: The review highlights AI's prowess in predicting HAIs, surpassing conventional methods. Existing evidence demonstrates AI's efficacy in accurately predicting and mitigating HAIs. Real‐time patient monitoring and alert systems powered by AI are shown to enhance infection detection and patient outcomes. The paper also addresses AI's role in automating sterilization and disinfection, with studies affirming its effectiveness in reducing infections. AI's resource optimization capabilities are exemplified in ICU settings, showcasing its potential to improve resource allocation efficiency. Furthermore, the review emphasizes AI's personalized approach to infection control post‐procedures, elucidating its ability to analyze patient data and create tailored control plans.

18 April 2023 in New Microbes and New Infections
Verified
Journal Article
Open access
NDNovonil Deb
Novonil Deb
PRPoulami Roy
Poulami Roy
VJVikash Jaiswal
Vikash Jaiswal
AMAroop Mohanty
Aroop Mohanty
SSSanjit Sah
Sanjit Sah
Ranjit SahRanjit Sah
Ranjit Sah

23 May 2024 in Discover Oncology
Verified
Journal Article
Open access
PDF file
TAToufik Abdul-Rahman
Toufik Abdul-Rahman
PRPoulami Roy
Poulami Roy
RHRanferi Eduardo Herrera-Calderón
Ranferi Eduardo Herrera-Calderón
FKFeriha Fatima Khidri
Feriha Fatima Khidri
QOQuadri Ajibola Omotesho
Quadri Ajibola Omotesho
AAAthanasios Alexiou
Athanasios Alexiou
Breast cancer (BC) continues to be a significant global challenge due to drug resistance and severe side effects. The increasing prevalence is alarming, requiring new therapeutic approaches to address these challenges. At this point, Extracellular vesicles (EVs), specifically small endosome-released nanometer-sized EVs (SEVs) or exosomes, have been explored by literature as potential theranostics. Therefore, this review aims to highlight the therapeutic potential of exosomes in BC, focusing on their advantages in drug delivery and their ability to mitigate metastasis. Following the review, we identified exosomes' potential in combination therapies, serving as miRNA carriers and contributing to improved anti-tumor effects. This is evident in clinical trials investigating exosomes in BC, which have shown their ability to boost chemotherapy efficacy by delivering drugs like paclitaxel (PTX) and doxorubicin (DOX). However, the translation of EVs into BC therapy is hindered by various challenges. These challenges include the heterogeneity of EVs, the selection of the appropriate parent cell, the loading procedures, and determining the optimal administration routes. Despite the promising therapeutic potential of EVs, these obstacles must be addressed to realize their benefits in BC treatment.

31 March 2024 in Medicina
Verified
Journal Article
Open access
PDF file
VJVikash Jaiswal
Vikash Jaiswal
SASong Peng Ang
Song Peng Ang
NDNovonil Deb
Novonil Deb
MHMUHAMMAD HANIf
MUHAMMAD HANIf
NBNitya Batra
Nitya Batra
Jishanth MattumpuramJishanth Mattumpuram
Jishanth Mattumpuram
Background: Chemotherapy-induced cardiac dysfunction (CIC) is a significant and concerning complication observed among cancer patients. Despite the demonstrated cardioprotective benefits of statins in various cardiovascular diseases, their effectiveness in mitigating CIC remains uncertain. Objective: This meta-analysis aims to comprehensively evaluate the potential cardioprotective role of statins in patients with CIC. Methods: A systematic literature search was conducted using PubMed, Embase, and Scopus databases to identify relevant articles published from inception until 10th May 2023. The outcomes were assessed using pooled odds ratio (OR) for categorical data and mean difference (MD) for continuous data, with corresponding 95% confidence intervals (95% CIs). Results: This meta-analysis comprised nine studies involving a total of 5532 patients, with 1904 in the statin group and 3628 in the non-statin group. The pooled analysis of primary outcome shows that patients who did not receive statin suffer a greater decline in the LVEF after chemotherapy compared to those who receive statin (MD, 3.55 (95% CI: 1.04–6.05), p = 0.01). Likewise, we observed a significantly higher final mean LVEF among chemotherapy patients with statin compared to the non-statin group of patients (MD, 2.08 (95% CI: 0.86–3.30), p > 0.001). Additionally, there was a lower risk of incident heart failure in the statin group compared to the non-statin group of patients (OR, 0.41 (95% CI: 0.27–0.62), p < 0.001). Lastly, the change in the mean difference for LVEDV was not statistically significant between the statin and non-statin groups (MD, 1.55 (95% CI: −5.22–8.33), p = 0.65). Conclusion: Among patients of CIC, statin use has shown cardioprotective benefits by improving left ventricular function and reducing the risk of heart failure.

19 May 2023 in Pediatric Neurology
Verified
Journal Article
Closed access
NDNovonil Deb
Novonil Deb
PRPoulami Roy
Poulami Roy
ABAnuradha Biswakarma
Anuradha Biswakarma
TMTherese Mary
Therese Mary
SMSanah Mahajan
Sanah Mahajan
ASAatam Shah
Aatam Shah